Video

Dr. Kopetz on the Design of the BEACON CRC Trial in BRAF V600E-Mutant mCRC

Author(s):

Scott Kopetz, MD, PhD, FACP

In Partnership With:

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer (mCRC).

In the multicenter, randomized, open-label, 3-arm BEACON CRC study, patients with BRAF V600E-mutant mCRC who progressed on 1 ​to 2 prior lines of therapy were randomized 1:1:1 to receive encorafenib (Braftovi) ​plus binimetinib (Mektovi) and cetuximab (Erbitux), encorafenib and cetuximab ​alone, or investigator's choice of cetuximab plus irinotecan or FOLFIRI, says Kopetz.

Initial results demonstrated encouraging clinical activity with ​the triplet regimen, Kopetz says. Encorafenib/binimetinib/cetuximab improve​d overall survival (OS) and overall response rates (ORR) ​compared with the cetuximab plus irinotecan-containing regimens.

The latest findings, which were presented during the 2020 ASCO Virtual Scientific Program, showed that the benefit in OS and ORR was maintained ​with the triplet compared with the control regimens, Kopetz concludes.

Related Videos
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD
Brandon Huffman, MD
Sattva S. Neelapu, MD
Related Content
Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center
June 3rd 2024

Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Shengfeng Li
June 3rd 2024

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center
June 2nd 2024

Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer

David R. Spigel, MD, of Sarah Cannon Research Institute
June 2nd 2024

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation